Investment
Features
FeesSafety
Academy
More
Pluang+

ADMA Biologics posts flat Q1 2026 revenue but strong profit growth and robust ASCENIV demand

Company Fundamentals
06 May 2026
GlobeNewsWire
View Source
Bullish
pluang ai news

ADMA Biologics reported Q1 2026 revenue of $114.5 million, flat year-over-year, with ASCENIV revenue up 28% and BIVIGAM down 54%. Despite market pressures and distributor inventory shifts affecting BIVIGAM, ASCENIV demand remained strong, driving 22% adjusted net income growth and 24% adjusted EBITDA growth. The company generated $58 million in operating cash flow and maintains a strong balance sheet, reaffirming confidence in ASCENIV's growth. ADMA updated its 2026 outlook with revenue expected between $530 million and $560 million but withdrew long-term guidance due to competitive market dynamics.

More News (ADMA)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App